Clinical trials: Atopic Dermatitis Eczema
Atopic Dermatitis
Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis
The purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.
- Trial name
- KAOS (NCT02920411)
- Testing
- Pediatopic Treatment Cream, Pediatopic Body lotion
- Where
- 2 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Laboratorios Ordesa
Contact Dermatitis, Eczema, Contact
Novel Topical Treatment of Hand Dermatitis (Eczema)
This study is designed as a prospective, randomized, double-blind right/left comparison of Epikeia coatings to improve hand dermatitis.
- Trial name
- NCT00614289
- Testing
- Epikeia Coatings
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Biomedical Development Corporation
Atopic Dermatitis
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse…
- Trial name
- NCT06552520
- Testing
- TQH2722 injection
- Where
- 73 sites in China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Atopic Dermatitis
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo.
- Trial name
- NCT05121480
- Testing
- EDP1815
- Where
- 59 sites in United States, Australia and 4 more
- Volunteers
- 421 people
- Sponsor
- Evelo Biosciences, Inc.
Acne, Atopic Dermatitis
Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis
The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected.
- Conditions
- Acne, Atopic Dermatitis, Psoriasis Vulgaris, Rosacea
- Trial name
- NCT04472546
- Testing
- in-vivo mesure, Scotch, Lipid index
- Where
- France
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Efficacy Evaluation and Cutaneous Acceptability of the Lipikar Med Product on Subjects With Atopic Dermatitis
In this study, we will test the tolerance of a topical product and its efficacy in reducing the atopy crisis duration and severity.
- Trial name
- NCT05531188
- Where
- Mauritius
- Volunteers
- 68 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Atopic dermatitis (AD) is a common skin disease that has increased in prevalence worldwide two- to threefold over the last 50 years.
- Trial name
- NCT00460083
- Testing
- Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ceragenix Pharmaceuticals
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Atopic Dermatitis
Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.
The investigators aimed to understand better the efficacy in a randomized, double-blind, intraindividual design trial in 66 participants with AD treated with SNG100, and 2 different strengths of topical steroids hydrocortisone…
- Trial name
- SNG100 (NCT04615962)
- Testing
- Hydrocortisone Acetate 1% Cream, Mometasone Furoate, SNG100
- Volunteers
- 66 people
- Sponsor
- Seanergy Dermatology Ltd.
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03363854
- Testing
- Tralokinumab
- Where
- 66 sites in United States, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
- Trial name
- NCT05717920
- Testing
- ADX-629 (Open-label)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis Eczema
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
This study was a Phase 3, multicenter, open-label extension study of the long-term safety of roflumilast cream 0.15% (completers of studies ARQ-151-311 or ARQ-151-312 aged ≥6 years and ARQ-151-315 rollovers who turned 6 years of…
- Trial name
- INTEGUMENT-OLE (NCT04804605)
- Testing
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,220 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Atopic Dermatitis
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e.
- Trial name
- NCT00925730
- Testing
- Pimecrolimus
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis
Dermatitis, Atopic
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- GENESIS (NCT04791319)
- Testing
- Bermekimab, Dupilumab
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Atopic Dermatitis
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study
- Trial name
- NCT06723080
- Testing
- VC005 low dose group, VC005 high dose group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
Atopic dermatitis (AD) is a common chronic inflammatory skin disease, affecting both children (15- 20%) and adults (2-5%). The pathogenesis of AD is complex and multifactorial, including skin barrier dysfunction and immune…
- Trial name
- NCT06983561
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary…
- Trial name
- NCT04992546
- Testing
- PRN473 (SAR444727)
- Where
- 12 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Principia Biopharma, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.